COVER STORY While rescuers labored to recover the bodies of those lost in the World Trade Center collapse, a small Michigan software company set about salvaging their identities.
By Melissa Kruse
The next generation of protein microarrays from the likes of Protometrix and Molecular Staging may work so well that drug companies won't want them.
By Mark D. UehlingNews·Analysis Small-Molecule Research Attracts NHGRIClinical IT Sumo WrestlersDown on the ‘Pharma’FDA Vision Quest Ends‘Once More Unto the Breach…’Desktop Linux Gets Ready for Prime TimeQ2 Results Fuel HopeNanobiotech Stew Bubbling but Not Yet Ready to EatHorizons
CombinatoRx brings matchmaking to drug discovery and development.
From "Poison Squad" to pharma watchdog, the ever-changing and controversial role of the FDA makes for fascinating history.
Is this the end of the in silico drug discovery and development market?
The Internet is an increasingly hostile environment. How safe is Web-based EDC?Columns
| Kevin Davies
A small bioinformatics company gets called into the national service.
| Kevin Davies
Microarrays reveal new insights into the pathogenesis and pharmacogenomics of cancer.
| Michael A. Greeley
Some emerging bio-IT services companies are beginning to attract venture capital.
| By Julia Boguslavsky
No longer just a "good idea," HCS is making an impact in target and lead selection.
| By John Russell
A week at The Jackson Laboratory reveals much of the nature of mice and men. Departments
· Roche Makes Waves with AmpliChip · Launcho Avaki's Grid Transforms Data for Collaboration · Anacubis App Maps Data, Reveals Connections